Technical analysis of Kodiak Sciences Inc. (KOD): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer.
Price Performance
| 1 month | +5.42% |
| 3 months | +117.82% |
| Year-to-date | +253.68% |
| 1 year | +446.35% |
| 3 years | +4090.25% |
| 5 years | +300.53% |
52-Week Range
| 52-week High | $104.00 |
| 52-week Low | $15.83 |
| Avg Volume (90d) | 1.4M |
Technical Indicators
| SMA 50 | $66.14 |
| SMA 200 | $42.81 |
| Beta | 2.40 |
| 30-day Volatility (annualised) | 299.6% |
| Price vs SMA 50 | +49.5% |
| Price vs SMA 200 | +131.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $27.96 | |
| 2026-01 | $22.77 | -18.6% |
| 2026-02 | $26.80 | +17.7% |
| 2026-03 | $38.12 | +42.2% |
| 2026-04 | $43.48 | +14.1% |
| 2026-05 | $36.71 | -15.6% |
| 2026-06 | $38.96 | +6.1% |
| 2026-07 | $41.58 | +6.7% |
| 2026-08 | $37.35 | -10.2% |
| 2026-09 | $94.80 | +153.8% |
| 2026-10 | $99.18 | +4.6% |
| 2026-11 | $98.89 | -0.3% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-12 | $-1.06 | |
| 2026-08-12 | $-0.96 | |
| 2026-05-07 | $-0.93 | |
| 2026-03-31 | $-1.02 | |
| 2025-11-13 | $-1.07 | |
| 2025-08-13 | $-1.01 | |
| 2025-05-14 | $-0.89 | |
Price
| Price | $98.89 (closing price, November 3, 2026) |
| Market Cap | $6.2B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 101.37 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 1.57 |
| Current Ratio | 2.49 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -3.23 |